Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
Ulrich Keilholz(German Cancer Research Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Dirk Schadendorf(National Center for Tumor Diseases), Cornelis J.A. Punt(Utrecht University), Alexander Schmittel(Franklin University), Thierry Velu(Radboud University Nijmegen), Jose Thomas(Radboud University Nijmegen), Frederic Lehman(Radboud University Nijmegen), Ulrich R. Kleeberg(European Organisation for Research and Treatment of Cancer), Stefan Suciu(St James's University Hospital), Poulam Patel(Radboud University Nijmegen), Danielle Líénard(University Hospital of Lausanne), Wim H.J. Kruit(Erasmus MC), Sylvie Négrier(Université Claude Bernard Lyon 1), Martin Gore(Imperial College London), Thomas M. Proebstle(Radboud University Nijmegen)
Cited by 166
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k